JP2018515570A - Ｂｒａｆ−ｖ６００関連疾患の治療に使用するためのｐｌｘ−８３９４またはｐｌｘ−７９０４ - Google Patents

Ｂｒａｆ−ｖ６００関連疾患の治療に使用するためのｐｌｘ−８３９４またはｐｌｘ−７９０４ Download PDF

Info

Publication number
JP2018515570A
JP2018515570A JP2017560716A JP2017560716A JP2018515570A JP 2018515570 A JP2018515570 A JP 2018515570A JP 2017560716 A JP2017560716 A JP 2017560716A JP 2017560716 A JP2017560716 A JP 2017560716A JP 2018515570 A JP2018515570 A JP 2018515570A
Authority
JP
Japan
Prior art keywords
braf
cancer
mutation
formula
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017560716A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018515570A5 (enExample
Inventor
プラブハ・エヌ・イブラヒム
チャオ・ジャン
ウェイン・スピバック
ジアジョン・ジャン
グオシエン・ウー
ジャック・リン
ハンナ・チョ
マリカ・ネスピ
ソンユエン・シ
トッド・ユーイング
イン・ジャン
ギデオン・ボラグ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Plexxikon Inc
Original Assignee
Plexxikon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Plexxikon Inc filed Critical Plexxikon Inc
Publication of JP2018515570A publication Critical patent/JP2018515570A/ja
Publication of JP2018515570A5 publication Critical patent/JP2018515570A5/ja
Priority to JP2021209544A priority Critical patent/JP2022058398A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
JP2017560716A 2015-05-22 2016-05-20 Ｂｒａｆ−ｖ６００関連疾患の治療に使用するためのｐｌｘ−８３９４またはｐｌｘ−７９０４ Pending JP2018515570A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021209544A JP2022058398A (ja) 2015-05-22 2021-12-23 Ｂｒａｆ－ｖ６００関連疾患の治療に使用するためのｐｌｘ－８３９４またはｐｌｘ－７９０４

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562165813P 2015-05-22 2015-05-22
US62/165,813 2015-05-22
PCT/US2016/033587 WO2016191296A1 (en) 2015-05-22 2016-05-20 Plx-8394 or plx-7904 for use in the treatment of braf-v600-related diseases

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021209544A Division JP2022058398A (ja) 2015-05-22 2021-12-23 Ｂｒａｆ－ｖ６００関連疾患の治療に使用するためのｐｌｘ－８３９４またはｐｌｘ－７９０４

Publications (2)

Publication Number Publication Date
JP2018515570A true JP2018515570A (ja) 2018-06-14
JP2018515570A5 JP2018515570A5 (enExample) 2019-06-20

Family

ID=56113075

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017560716A Pending JP2018515570A (ja) 2015-05-22 2016-05-20 Ｂｒａｆ−ｖ６００関連疾患の治療に使用するためのｐｌｘ−８３９４またはｐｌｘ−７９０４
JP2021209544A Pending JP2022058398A (ja) 2015-05-22 2021-12-23 Ｂｒａｆ－ｖ６００関連疾患の治療に使用するためのｐｌｘ－８３９４またはｐｌｘ－７９０４

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021209544A Pending JP2022058398A (ja) 2015-05-22 2021-12-23 Ｂｒａｆ－ｖ６００関連疾患の治療に使用するためのｐｌｘ－８３９４またはｐｌｘ－７９０４

Country Status (9)

Country Link
US (1) US9814714B2 (enExample)
EP (1) EP3297630A1 (enExample)
JP (2) JP2018515570A (enExample)
KR (1) KR20180006447A (enExample)
CN (2) CN113893253A (enExample)
BR (1) BR112017025045A2 (enExample)
CA (1) CA2986739C (enExample)
TW (1) TWI812581B (enExample)
WO (1) WO2016191296A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022531609A (ja) * 2019-12-10 2022-07-07 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 新規メチルキナゾリノン誘導体
JP2023505300A (ja) * 2019-12-10 2023-02-08 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト パラドックス遮断剤としての新規ｂｒａｆ阻害剤

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG183036A1 (en) 2007-07-17 2012-08-30 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor
AU2012214762B2 (en) 2011-02-07 2015-08-13 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
US9358235B2 (en) 2012-03-19 2016-06-07 Plexxikon Inc. Kinase modulation, and indications therefor
MX2015002887A (es) 2012-09-06 2015-07-06 Plexxikon Inc Compuestos y metodos para la modulacion de cinasas, e indicaciones para ello.
DK2935248T3 (en) 2012-12-21 2018-04-23 Plexxikon Inc RELATIONS AND PROCEDURE FOR CHINESE MODULATION AND INDICATIONS THEREOF
US20140303121A1 (en) 2013-03-15 2014-10-09 Plexxikon Inc. Heterocyclic compounds and uses thereof
SMT201800650T1 (it) 2013-03-15 2019-01-11 Plexxikon Inc Composti eterociclici e loro impiego
KR20160013028A (ko) 2013-05-30 2016-02-03 플렉시콘, 인코퍼레이티드 키나제 조정을 위한 화합물 및 그에 대한 적응증
US10160755B2 (en) 2015-04-08 2018-12-25 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
HUE047657T2 (hu) 2015-05-06 2020-05-28 Plexxikon Inc Kináz-moduláló hatású 1H-pirrolo[2,3-b]piridin származékok szintézise
WO2016179415A1 (en) 2015-05-06 2016-11-10 Plexxikon Inc. Solid forms of a compound modulating kinases
JP6722200B2 (ja) 2015-05-22 2020-07-15 プレキシコン インコーポレーテッドＰｌｅｘｘｉｋｏｎ Ｉｎｃ． 複素環化合物の合成
US10829484B2 (en) 2015-07-28 2020-11-10 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
CA3129180A1 (en) 2015-09-21 2017-03-30 Plexxikon Inc. Heterocyclic compounds and uses thereof
WO2017100201A1 (en) 2015-12-07 2017-06-15 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
CA3017972C (en) 2016-03-16 2023-03-28 Plexxikon Inc. Compounds and methods for kinase modulation and indications therefore
TW201815766A (zh) 2016-09-22 2018-05-01 美商普雷辛肯公司 用於ｉｄｏ及ｔｄｏ調節之化合物及方法以及其適應症
US10703757B2 (en) 2016-12-23 2020-07-07 Plexxikon Inc. Compounds and methods for CDK8 modulation and indications therefor
US11040027B2 (en) 2017-01-17 2021-06-22 Heparegenix Gmbh Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
WO2018175311A1 (en) 2017-03-20 2018-09-27 Plexxikon Inc. Crystalline forms of 4-(1-(1,1-di(pyridin-2-yl)ethyl)-6-(3,5-dimethylisoxazol-4-yl)-1h- pyrrolo[3,2-b]pyridin-3-yl)benzoic acid that inhibits bromodomain
WO2018218633A1 (en) * 2017-06-02 2018-12-06 Beijing Percans Oncology Co. Ltd. Combination therapies for treating cancers
US10428067B2 (en) 2017-06-07 2019-10-01 Plexxikon Inc. Compounds and methods for kinase modulation
JP7170030B2 (ja) 2017-07-25 2022-11-11 プレキシコン インコーポレーテッド キナーゼを調節する化合物の製剤
JP7675519B2 (ja) 2017-10-13 2025-05-13 オプナ バイオ ソシエテ アノニム キナーゼを調節するための化合物の固体形態
JP7175309B2 (ja) * 2017-10-27 2022-11-18 プレキシコン インコーポレーテッド キナーゼを調節する化合物の製剤
CA3094336A1 (en) 2018-03-20 2019-09-26 Plexxikon Inc. Compounds and methods for ido and tdo modulation, and indications therefor
WO2019195959A1 (en) 2018-04-08 2019-10-17 Cothera Biosciences, Inc. Combination therapy for cancers with braf mutation
CN108864060A (zh) * 2018-06-03 2018-11-23 刘思良 一种重氮类衍生物及其在癌症治疗中的应用
CN108610336A (zh) * 2018-06-03 2018-10-02 刘思良 一种重氮类衍生物及其在癌症治疗中的应用
CN108586439A (zh) * 2018-06-03 2018-09-28 刘思良 一种Raf激酶抑制剂及其在癌症治疗中的应用
WO2020036852A1 (en) 2018-08-13 2020-02-20 Beijing Percans Oncology Co. Ltd. Biomarkers for cancer therapy
EP3873445A4 (en) * 2018-10-30 2022-09-07 Institute For Cancer Research d/b/a The Research Institute of Fox Chase Cancer Center COMBINATION THERAPIES FOR THE TREATMENT OF CANCER
BR112021019957A2 (pt) 2019-04-09 2021-12-07 Plexxikon Inc Azinas condensadas para modulação de ep300 ou cbp e indicações da mesma
CN110585433A (zh) * 2019-09-27 2019-12-20 青岛大学 Braf-v600e的抑制剂的应用及用于治疗甲状腺癌的药物
US12509444B2 (en) 2019-12-06 2025-12-30 Plexxikon Inc. Compounds and methods for CD73 modulation and indications therefor
CN118767143A (zh) 2019-12-12 2024-10-15 听治疗有限责任公司 用于预防和治疗听力损失的组合物和方法
CN111057690A (zh) * 2019-12-23 2020-04-24 维塔恩(广州)医药有限公司 肿瘤相关基因braf突变相关抗原短肽及其应用
US11807626B2 (en) 2020-04-23 2023-11-07 Opna Bio SA Compounds and methods for CD73 modulation and indications therefor
MX2022013597A (es) 2020-04-29 2023-03-22 Plexxikon Inc Sintesis de compuestos heterociclicos.
CA3192047A1 (en) 2020-08-21 2022-02-24 Plexxikon Inc. Combinational drug anticancer therapies
WO2023049798A1 (en) * 2021-09-22 2023-03-30 Henry Ford Health System Hdac3 inhibitors for the treatment of langerhans cell histiocytosis and langerhans cell sarcoma
CN118845777B (zh) * 2024-06-28 2025-02-25 遵义医科大学附属医院 一种克诺拉尼用作淋巴水肿治疗剂的用途

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014504640A (ja) * 2011-02-07 2014-02-24 プレキシコン インコーポレーテッド キナーゼ調節のための化合物および方法、ならびにそれに対する適応症
WO2014147573A2 (en) * 2013-03-21 2014-09-25 Novartis Ag Combination therapy
WO2014194127A1 (en) * 2013-05-30 2014-12-04 Plexxikon Inc. Compounds for kinase modulation, and indications therefor

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1893612T3 (pl) 2005-06-22 2012-01-31 Plexxikon Inc Pochodne pirolo-[2,3-b]pirydyny jako inhibitory kinazy białkowej
WO2008063888A2 (en) 2006-11-22 2008-05-29 Plexxikon, Inc. Compounds modulating c-fms and/or c-kit activity and uses therefor
SG183036A1 (en) 2007-07-17 2012-08-30 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor
WO2009143018A2 (en) 2008-05-19 2009-11-26 Plexxikon, Inc. Compounds and methods for kinase modulation, and indications therefor
NZ594398A (en) 2009-04-03 2014-03-28 Plexxikon Inc Propane-1-sulfonic acid (3-[5-(4-chloro-phenyl)-1h-pyrrol [2, 3-b] pyridine-3-carbonyl]-2,4-difluoro-phenyl} -amide compositions and uses thereof
CN105906631A (zh) 2009-11-18 2016-08-31 普莱希科公司 用于激酶调节的化合物和方法及其适应症
MX2012007429A (es) 2009-12-23 2012-07-23 Plexxikon Inc Compuestos y metodos para la modulacion de quinasa e indicaciones de la misma.
SG194847A1 (en) 2011-05-17 2013-12-30 Plexxikon Inc Kinase modulation and indications therefor
US9358235B2 (en) 2012-03-19 2016-06-07 Plexxikon Inc. Kinase modulation, and indications therefor
CA2879252C (en) * 2012-08-17 2017-10-10 F. Hoffmann-La Roche Ag Combination therapies for melanoma comprising administering cobimetinib and vemurafinib
US20140303121A1 (en) 2013-03-15 2014-10-09 Plexxikon Inc. Heterocyclic compounds and uses thereof
EP3194392B1 (en) 2014-09-15 2020-01-01 Plexxikon, Inc. Heterocyclic compounds and uses thereof
US10160755B2 (en) 2015-04-08 2018-12-25 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
WO2016179415A1 (en) 2015-05-06 2016-11-10 Plexxikon Inc. Solid forms of a compound modulating kinases
JP6722200B2 (ja) 2015-05-22 2020-07-15 プレキシコン インコーポレーテッドＰｌｅｘｘｉｋｏｎ Ｉｎｃ． 複素環化合物の合成
US10829484B2 (en) 2015-07-28 2020-11-10 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
CA3129180A1 (en) 2015-09-21 2017-03-30 Plexxikon Inc. Heterocyclic compounds and uses thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014504640A (ja) * 2011-02-07 2014-02-24 プレキシコン インコーポレーテッド キナーゼ調節のための化合物および方法、ならびにそれに対する適応症
WO2014147573A2 (en) * 2013-03-21 2014-09-25 Novartis Ag Combination therapy
JP2016522160A (ja) * 2013-03-21 2016-07-28 ノバルティス アーゲー 併用療法
WO2014194127A1 (en) * 2013-05-30 2014-12-04 Plexxikon Inc. Compounds for kinase modulation, and indications therefor

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JAEHYUK CHOI: "IDENTIFICATION OF PLX4032-RESISTANCE MECHANISMS AND IMPLICATIONS FOR NOVEL RAF INHIBITORS", PIGMENT CELL & MELANOMA RESEARCH, vol. VOL:27, NR:2, JPN5018002695, 6 January 2014 (2014-01-06), pages 253 - 262, ISSN: 0004369888 *
POULIKAKOS, POULIKOS I. ET AL., NATURE, vol. 464, JPN6020013539, March 2010 (2010-03-01), pages 427 - 431, ISSN: 0004369889 *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022531609A (ja) * 2019-12-10 2022-07-07 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 新規メチルキナゾリノン誘導体
JP7108146B2 (ja) 2019-12-10 2022-07-27 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 新規メチルキナゾリノン誘導体
JP2022124458A (ja) * 2019-12-10 2022-08-25 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 新規メチルキナゾリノン誘導体
JP2023505300A (ja) * 2019-12-10 2023-02-08 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト パラドックス遮断剤としての新規ｂｒａｆ阻害剤
US12116349B2 (en) 2019-12-10 2024-10-15 Hoffmann-La Roche Inc. Methylquinazolinone derivatives
JP7788380B2 (ja) 2019-12-10 2025-12-18 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト パラドックス遮断剤としての新規ｂｒａｆ阻害剤

Also Published As

Publication number Publication date
WO2016191296A1 (en) 2016-12-01
TW201707704A (zh) 2017-03-01
CN107801378A (zh) 2018-03-13
CN113893253A (zh) 2022-01-07
US20160339025A1 (en) 2016-11-24
CA2986739C (en) 2023-03-14
JP2022058398A (ja) 2022-04-12
CA2986739A1 (en) 2016-12-01
US9814714B2 (en) 2017-11-14
BR112017025045A2 (pt) 2018-08-07
EP3297630A1 (en) 2018-03-28
TWI812581B (zh) 2023-08-21
KR20180006447A (ko) 2018-01-17

Similar Documents

Publication Publication Date Title
US9814714B2 (en) Kinase modulation, and indications therefor
JP7086251B2 (ja) ヘテロ環式化合物およびそれらの使用
TWI803530B (zh) 調節激酶之化合物之調配物
ES2820827T3 (es) Formas sólidas de un compuesto modulador de quinasas
US9771369B2 (en) Compounds and methods for kinase modulation, and indications therefor
TW201922742A (zh) 用於調節激酶之化合物固體形式
RU2672910C9 (ru) Гетероароматические соединения как модуляторы фосфоинозитид-3-киназы
CN107427522A (zh) 用于治疗黑素瘤的阿吡莫德
HK40036046B (en) Formulations of a compound modulating kinases
HK40036046A (en) Formulations of a compound modulating kinases

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190514

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190514

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20200325

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200407

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200707

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20201027

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20201209

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210426

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20210824

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211223

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20211223

C11 Written invitation by the commissioner to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C11

Effective date: 20220111

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20220215

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20220222

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20220325

C211 Notice of termination of reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C211

Effective date: 20220329

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20230314

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20230411

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230804